The Greifswalder Coldplasmatech GmbH, a multi-award-winning MedTech startup and member of the Gründungswerft, has achieved a significant milestone.
With the US-based Royal Biologics, a leading provider in the field of wound care, the company is entering into a strategic partnership. Royal Biologics is the world market leader for orthobiologic and advanced wound care solutions.
Goal: The international expansion of their innovative cold plasma technology for the treatment of chronic wounds.
High-tech against a silent epidemic
Almost a billion people worldwide suffer from chronic or poorly healing wounds. In the USA, they cause annual healthcare costs of around 50 billion dollars. Previous therapies often reach their limits – especially when multidrug-resistant germs are involved.
Coldplasmatech offers with the CPT®cube and the CPT®patch a groundbreaking solution: Using ionized gas (cold plasma), a bioactive environment is created that kills germs and activates healing – in just two minutes per treatment. And all of this is painless, automated, and easily usable in clinics.
A real gamechanger
Salvatore Leo, CEO of Royal Biologics, is thrilled: „Coldplasmatech takes wound care to a whole new level. The technology is not only effective, but also scalable – this opens up completely new perspectives for patients worldwide.“
Dr. Carsten Mahrenholz, CEO of Coldplasmatech, also emphasizes the importance of the partnership: „With Royal Biologics, we have gained a strong partner who not only offers market access in the USA, but also shares our vision: rethinking wound care – evidence-based, patient-centered and forward-looking.“
From university spin-off to international MedTech player
Coldplasmatech was founded in 2015 as a spin-off of the Leibniz Institute for Plasma Research in Greifswald and has since developed into a model company in the region.
Numerous awards, including the German and the Bavarian Innovation Prize, demonstrate the innovation potential.
Currently, the company is conducting the world’s largest randomized study on the treatment of chronic wounds with the POWER study – funded by the Federal Ministry of Education and Research. Greifswald technology for the world
The new partnership brings not only capital, but also international expertise, visibility and new distribution channels – an important step for the growth of Coldplasmatech and a strong signal for the innovation location Greifswald and the entire startup scene in Mecklenburg-Vorpommern.
Further Links
https://www.coldplasmatech.com website and https://www.royalbiologics.com website
